Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. plasmid dna
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Plasmid Dna Articles & Analysis: Older

22 news found

Alfa Chemistry Announces the Launch of Innovative IVD Products for Laboratory Use

Alfa Chemistry Announces the Launch of Innovative IVD Products for Laboratory Use

The biological reagents previously launched by Alfa Chemistry encompass transilluminator, proteomic products (i.e., Protein Marker/Ladder, Western Substrate, Protein Staining Reagent, OneStep Blocker, UltraScence TMB ELISA Substrate), genomic products (i.e., DNA Marker/Ladder, Staining Reagent, Agarose, PCR Reagent, RNA Reagent, Real-Time PCR Reagent), and nucleic acid ...

ByAlfa Chemistry


CD Bioparticles Launches mRNA Transfection Reagents for Research Applications

CD Bioparticles Launches mRNA Transfection Reagents for Research Applications

Due to the elimination of the transcription process, mRNA transfection involves only translation and yields faster and more direct results than DNA transfection. Of course, mRNA transfection is limited to instantaneous expressions. Unlike DNA and viral vectors, mRNA will not be inserted into the host genomes that modify genetic information, and proteins encoded ...

ByCD Bioparticles


CD Bioparticles Announces Magnetofection Reagents for Gene Expression

CD Bioparticles Announces Magnetofection Reagents for Gene Expression

By utilizing the Lipofection and Magnetofection transfection techniques, these reagents are suitable for all types of nucleic acids, including plasmid DNA, linearized DNA, siRNA, oligonucleotides, double-stranded RNA, mRNA, and shRNA. ...

ByCD Bioparticles


Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Eikonoklastes will utilize Forge’s platform process including its proprietary HEK 293 suspension Ignition Cells™ and pEMBR™ adenovirus helper plasmid. All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio. ...

ByForge Biologics, Inc.


Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray ...

ByForge Biologics, Inc.


Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership

Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership

Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials ...

ByForge Biologics, Inc.


Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients

Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients

Research-Grade and GMP-Pathway plasmid grades are currently available, with cGMP plasmid production available in 2023. ...

ByForge Biologics, Inc.


Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine

Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine

This mechanism leads to enhanced and prolonged protein expression levels at lower doses compared to conventional mRNA. Plasmid DNA Manufacturing Services Plasmid DNA is a critical starting material in the development of many advanced therapies. This collaboration will leverage Charles River’s industry leading expertise in ...

ByZiphius Vaccines NV


Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A

Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A

The collaboration will take advantage of Charles River’s end-to-end CDMO capabilities, building on the Company’s acquisitions of Cognate BioServices, Cobra Biologics, and Vigene Biosciences in 2021 that expanded its comprehensive cell and gene therapy portfolio to span each of the major CDMO platforms – cell therapy, viral vector and plasmid DNA ...

ByASC Therapeutics


First patient dosed in SCIB1 Phase 2 clinical trial

First patient dosed in SCIB1 Phase 2 clinical trial

This is achieved by delivering a DNA plasmid using Ichor’s TriGrid® 2.0 electroporation delivery device to enhance the uptake and presentation of cancer antigens to harness high avidity T cell responses. ...

ByScancell


CHA Medical & Bio Group Announces Groundbreaking for Its New Cell Gene Biobank Facility

CHA Medical & Bio Group Announces Groundbreaking for Its New Cell Gene Biobank Facility

Within the facility, the space dedicated for cell and gene therapy will offer integrated CDMO services for mRNA, viral vectors, and plasmid DNA, providing GMP production with multiple segregated cleanrooms to deliver greater manufacturing efficiency. ...

ByMatica Biotechnology, Inc.


< Back to Home  Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors

< Back to Home Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors

About Wacker Biotech Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are full-service contract manufacturers of therapeutic proteins, live microbial products (LMPs), vaccines based on microbial systems, and of plasmid DNA. Wacker Biotech's portfolio extends from strain/process development and analytical testing through to production for ...

ByActym Therapeutics


INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) ...

ByINOVIO Pharmaceuticals


INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

INO-4201 is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. ...

ByINOVIO Pharmaceuticals


INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

"DNA medicines" are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. ...

ByINOVIO Pharmaceuticals


Thermo Fisher Scientific Showcases Investment and Innovation During CPhI Worldwide 2021

Thermo Fisher Scientific Showcases Investment and Innovation During CPhI Worldwide 2021

The company opened its new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., to support the production of commercial plasmid DNA used as a raw material or as a primary drug substance for gene-based therapies. ...

ByThermo Fisher Scientific


Thermo Fisher Scientific To Showcase Investments and Innovation at DCAT Week 2021

Thermo Fisher Scientific To Showcase Investments and Innovation at DCAT Week 2021

Thermo Fisher will open its new cGMP plasmid DNA manufacturing facility this week in Carlsbad, Calif., which will enable the production of commercial plasmid DNA used as a raw material or as a primary drug substance for gene-based therapies. ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


Expanded Gene Therapy Portfolio Supports More Efficient Adeno-Associated Viral Manufacturing

Expanded Gene Therapy Portfolio Supports More Efficient Adeno-Associated Viral Manufacturing

The easy-to-use Applied Biosystems resDNASEQ Quantitative Plasmid DNA - Kanamycin Resistance Gene Kit* offers an all-in-one solution for precise and rapid measurement of residual plasmid DNA. ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI). DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. ...

ByINOVIO Pharmaceuticals


INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...

ByINOVIO Pharmaceuticals

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT